Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan | Anticancer Research
Cancers | Free Full-Text | Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer
JCM | Free Full-Text | Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer | NEJM
Paclitaxel (Taxol) | NEJM
Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial - ScienceDirect
Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours | Nature Biomedical Engineering
Breast Pathway Group – EC x 4 – Accelerated Paclitaxel x 4: Epirubicin & Cyclophosphamide x 4 followed by Accelerated Pa
12x Chemo, eisgekühlt bitte! Neuer Wirkstoff Paclitaxel
JAMA Network Open on Twitter: "RCT: Epirubicin + paclitaxel was non-inferior to the standard epirubicin + cyclophosphamide followed by paclitaxel in patients with operable HRBB2 negative and lymph nodes-positive breast cancer. https://t.co/Z672x44dQL
Mechanisms for the transport and accumulation of albumin-bound... | Download Scientific Diagram
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
A novel preventive therapy for paclitaxel-induced cognitive deficits: preclinical evidence from C57BL/6 mice | Translational Psychiatry
Mammakarzinom: 4x AC + 12x Paclitaxel anstelle von 4x EC + 12x Paclitaxel
Frontiers | Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
Approved for use in:
Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways | Oncogene
JPM | Free Full-Text | Immunotherapy for Squamous Esophageal Cancer: A Review
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel | Scientific Reports
Paclitaxel | Antitumor Agent | MedChemExpress
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study | British Journal of Cancer
